Navigation Links
Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia
Date:6/29/2009

SOUTHAMPTON, England, June 29 /PRNewswire/ -- Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased osmolality and decreased urine output. The study also found that VA106483 was generally well tolerated among the patient population.

Nocturia (defined as waking frequently to urinate at night thereby disturbing sleep significantly) is a common condition, with prevalence increasing markedly with age. It is often the presenting symptom in men with benign prostatic hypertrophy (BPH) and affects at least 70% of BPH patients. There is currently no adequate treatment for nocturia and it represents a potential market estimated at more than US$500 million.

VA106483 is a novel small molecule drug candidate that exerts its effect directly in the kidney by binding to vasopressin (V2) receptors, which regulate water balance. It was discovered by Vantia from its extensive drug candidate library.

The double-blind, placebo-controlled, dose-response study was designed to investigate the pharmacodynamics and pharmacokinetics of single and repeated oral doses of VA106483. The trial involved 27 elderly men aged 65 years or more with a history of nocturia.

Based on these results, Vantia now plans to advance VA106483 into a larger Phase IIb clinical efficacy study in the second half of 2009.

Dr Jim Phillips, CEO of Vantia Therapeutics, said 'VA106483 was discovered and has been developed by Vantia based on its small molecule drug development expertise and is the first of several potentially high-value drug candidates in our pipeline. The c
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3

Related medicine technology :

1. Vantia Therapeutics Pipeline Continues to Mature
2. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
3. Horizon Therapeutics HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
4. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
5. Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
6. Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
7. Oxford BioTherapeutics and GlaxoSmithKline Form Strategic Alliance to Develop Novel Cancer Therapeutic Antibodies
8. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
9. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
10. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
11. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...e-FirstCall/ -- Derma Sciences, Inc. (OTC Bull...re products, announced plans to release its third ...mber 16, 2009. The Company will hold a conference ... am EST. Interested parties should call (866) 788-... with passcode 81416481 to access the call. You ma...
(Date:11/6/2009)...-FirstCall/ -- Virtual Health Technologies, Inc. (... previously confirmed Letter of Intent to sell all...chnologies, Inc (WNDM) is subject to final approva...HGI. ,, Shareholder Assurances ,, "We be...tream and cash realized from the transaction would...
(Date:11/6/2009)...Call/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: ...ember 10, 2009 at 8:30 a.m. EST to discuss the thi...look for the remainder of 2009. Ron Bentsur, Chie...call. Keryx will announce its financial results f...or to the call. ,, In order to participate in t...
Breaking Medicine Technology:Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 3OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 4Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2Survey Demonstrates Marin County Residents Support Locally Owned and Operated Marin General Hospital 54452 1Survey Demonstrates Marin County Residents Support Locally Owned and Operated Marin General Hospital 54452 2St Jude Appoints New Senior Vice President of Public Relations 54447 1St Jude Appoints New Senior Vice President of Public Relations 54447 2Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48 Year Exemplary Record of Quality 54443 1Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48 Year Exemplary Record of Quality 54443 2
...Risk of death at five years is lower for aneurysm ...o surgical clipping , , NATICK, Mass., May 26 Bo...elcomed publication of results from the ISAT clini... with a ruptured intracranial aneurysm treated wit...ss likely to die within five years compared to pat...
...Data Confirm Tapentadol Efficacy and Tolerability ... It is estimated that up to 30 percent of all peo...ide effects, such as nausea and vomiting. The use ...is a leading risk factor for experiencing these si...and bothersome and can have an impact on a patient...
Other Medicine Technology:Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial 2Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial 3Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial 4New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 2New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 3New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 4New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 5New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 6New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 7New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal 8
(Date:11/6/2009)... Nov. 6 Authentidate Holding Corp. (Nasdaq: ADAT...ion Exchange and workflow management services, has...; Healthcare to be easily integrated with one of t..., Definitive Homecare Solutions, CPR+(TM). Inscry...ted Solutions Provider program, a program designed...
(Date:11/6/2009)...t of America, Inc. (the "REIT"), a self-managed, n... the execution of a Purchase and Sale Agreement (t...ng located in Englewood, Colorado for approximatel...r is located within the Englewood City Center, a t... Hampden Place is located near the Swedish Medical...
(Date:11/6/2009)...a leading children,s development organization with...n asked to deliver eight presentations on children...Public Health Association,s (APHA) Annual Meeting ...November 7-11, 2009. ,, The American Public Healt...dress current and emerging health science, policy,...
(Date:11/6/2009)...ert more pressure from the lungs, researchers say ...monal fluctuations make it harder for women to sin...fessional singers have difficulty singing while pr...because of hormones or other causes, such as decre...udy, researchers followed a professionally trained...
(Date:11/6/2009)...h 8 million more due next week, , , FRIDAY...ses of H1N1 swine flu vaccine available in the Uni...than a week ago -- most Americans who want a shot ...ficials acknowledged Friday. , In fact, 70 percent... get vaccinated couldn,t, according to a poll cond...
Breaking Medicine News(10 mins):Health News:Authentidate Introduces New Interface for Inscrybe Healthcare with Definitive Homecare Solutions' CPR+ 2Health News:Authentidate Introduces New Interface for Inscrybe Healthcare with Definitive Homecare Solutions' CPR+ 3Health News:Authentidate Introduces New Interface for Inscrybe Healthcare with Definitive Homecare Solutions' CPR+ 4Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 66,339 SF Medical Office Building Located in Englewood, Colorado 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 66,339 SF Medical Office Building Located in Englewood, Colorado 3Health News:Plan's Expertise Highlighted at Premier Health Forum 2Health News:Most Who Want Swine Flu Shot Can't Get It 2Health News:Most Who Want Swine Flu Shot Can't Get It 3
...about the ill effects of coffee, coffee drinkers f...has shown that people// who drink one to three cup...me extent. This research was part of the Iowa W...ffee. These antioxidants protect cells from damag...
...as offered to set up an ultra-modern medical colle... Bihar//. Jha said his desire to turn the Mat...ed medical college and hospital was part of his go...sit here Friday. Jha's announcement has come...
...rnment has increased its health budget by over 30 ...s and open a new medical college//. "In a bid...ent has increased the medical education department...ly plans to provide more funds for the purchase of...
... lowering cholesterol have been found to be useful...nti-cholesterol statin drugs are helpful in improv...reducing the risk of diabetic retinopathy and othe...ily 20-milligram dose of the statin drug simvastat...
... severe form of food poisoning, now has a new reme...of researchers working at the University of Bristo...edicine. The researchers have narrowed down on a p... been considered for the treatment of listeriosis,...
...d by a team at Queeen's has suggested that patient...n hooked up to dialysis// yield better results in ...amina. This five-month, exercise intervention...Respiratory (CCR) group at Queen's, and a group of...
Other Medicine News:Health News:Exercise Combined with Dialysis Yields Better Results 2
...r, Model II, is very simple to use and, furthermor...ned because it is only necessary to coincide the s...cales then indicating the pupillary distance, as w...nts between the centers of spectacle lenses and th...
...reenoscope provides fast, accurate, and reliable t... optical system duplicates conditions for viewing ...es conditions for near point test charts at 30cm (...ncorporates test charts that can be interchanged a...
...ce into the future with the all-new EXAM-3000! Per...fficiency, dramatically increase your patient flow...money. Todays demand for delegation and connectivi...or the progressive practice. Compare the new EXAM-...
Topcon OM-4 Ophthalmometer
Medicine Products: